ID

17711

Description

Study part: Dose-Limiting Toxicity LeMLAR-Studie. Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial. Publication granted by Prof. Dührsen and provided by Claudia Ose, University clinic Essen, NCT01788189, Version 1.3-28.04.2013.doc.

Keywords

  1. 9/28/16 9/28/16 -
Uploaded on

September 28, 2016

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Dose-Limiting Toxicity LeMLAR-Studie Lymphoma NCT01788189

Dose-Limiting Toxicity (only cycle 1 and 2)

LeMLAR-Dosisstufe
Description

LeMLAR-Dosisstufe

Alias
UMLS CUI-1
C0178602
Dose-limiting Toxicity DLT
Description

dose-limiting Toxicity

Data type

boolean

Alias
UMLS CUI [1,1]
C1512043
UMLS CUI [1,2]
C0013221
Datum der DLT:
Description

date dose-limiting Toxicity

Data type

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C1512043
UMLS CUI [1,3]
C0013221
Patientenidentifikation
Description

patient ID

Data type

integer

Alias
UMLS CUI [1]
C1269815
Methotrexat:
Description

dosage Methotrexate

Data type

float

Measurement units
  • mg/m²
Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C0025677
mg/m²
Cytarabin:
Description

dose Cytarabine

Data type

float

Measurement units
  • mg/m²
Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C0010711
mg/m²
Dosis-limitierende Toxizität in Zyklus 1
Description

dose-limiting Toxicity

Data type

boolean

Alias
UMLS CUI [1,1]
C1512043
UMLS CUI [1,2]
C0013221
Dosis-limitierende Toxizität in Zyklus 2
Description

dose-limiting Toxicity

Data type

boolean

Alias
UMLS CUI [1,1]
C1512043
UMLS CUI [1,2]
C0013221
Unzureichende Voraussetzung für die Therapiefortsetzung an Tag 8 (+ ≤ 3 Tage)
Description

therapy continued

Data type

boolean

Alias
UMLS CUI [1]
C3494713
Unzureichende Voraussetzung für die Therapiefortsetzung an Tag 15 (+ ≤ 6 Tage)
Description

therapy continued

Data type

boolean

Alias
UMLS CUI [1]
C3494713
Unzureichende Voraussetzung für die Therapiefortsetzung an Tag 29 (+ ≤ 7 Tage)
Description

therapy continued

Data type

boolean

Alias
UMLS CUI [1]
C3494713
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Granulozyten < 0.5/nl
Description

therapy continued granulocyte

Data type

boolean

Alias
UMLS CUI [1,1]
C3494713
UMLS CUI [1,2]
C0018183
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Thrombozyten < 25/nl
Description

therapy continued Blood Platelets

Data type

boolean

Alias
UMLS CUI [1,1]
C3494713
UMLS CUI [1,2]
C0005821
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Kreatinin-Clearance < 60 ml/min
Description

therapy continued Creatinine clearance measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C3494713
UMLS CUI [1,2]
C0373595
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Bilirubin ≥ 3.0 mg/dl
Description

therapy continued Bilirubin

Data type

boolean

Alias
UMLS CUI [1,1]
C3494713
UMLS CUI [1,2]
C0005437
Unzureichende Voraussetzung für die Therapiefortsetzung wegen GOT ≥ 6 x obere Normgrenze
Description

therapy continued GOT

Data type

boolean

Alias
UMLS CUI [1,1]
C3494713
UMLS CUI [1,2]
C0201899
Unzureichende Voraussetzung für die Therapiefortsetzung wegen GPT ≥ 6 x obere Normgrenze
Description

therapy continued GPT

Data type

boolean

Alias
UMLS CUI [1,1]
C3494713
UMLS CUI [1,2]
C0201836
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Mukositis Grad 3 oder 4
Description

therapy continued mucositis

Data type

boolean

Alias
UMLS CUI [1,1]
C3494713
UMLS CUI [1,2]
C0333355
Dosisreduktion von Methotrexat erforderlich
Description

Dosage Reduction Methotrexate

Data type

boolean

Alias
UMLS CUI [1,1]
C0178602
UMLS CUI [1,2]
C0441610
UMLS CUI [1,3]
C0025677
Verabreichte Dosis
Description

dosage Methotrexate

Data type

float

Measurement units
  • mg
Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C0025677
mg
An Tag
Description

day dosage Methotrexate

Data type

integer

Alias
UMLS CUI [1,1]
C0439228
UMLS CUI [1,2]
C3174092
UMLS CUI [1,3]
C0025677
Dosisreduktion von Cytarabin erforderlich
Description

Dosage Reduction Cytarabine

Data type

boolean

Alias
UMLS CUI [1,1]
C0178602
UMLS CUI [1,2]
C0441610
UMLS CUI [1,3]
C0010711
Verabreichte Dosis
Description

dosage Cytarabine

Data type

float

Measurement units
  • mg
Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C0010711
mg
An Tag
Description

day dosage Cytarabine

Data type

integer

Alias
UMLS CUI [1,1]
C0439228
UMLS CUI [1,2]
C3174092
UMLS CUI [1,3]
C0010711
Lenalidomid-Therapie < 21 Tage pro Zyklus
Description

Therapy Lenalidomide

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1144149
Anderweitige Toxizität, die die protokollgerechte Therapiefortführung verbietet
Description

toxicity Therapy cessation

Data type

boolean

Alias
UMLS CUI [1,1]
C0013221
UMLS CUI [1,2]
C1699848
Beschreibung der Toxizität:
Description

toxicity

Data type

text

Alias
UMLS CUI [1]
C0013221
UE-Nummer(n):
Description

UE-Number

Data type

integer

Weitere Kommentare
Description

comments

Data type

text

Alias
UMLS CUI [1]
C0947611
Datum der Bearbeitung
Description

date

Data type

date

Alias
UMLS CUI [1]
C0011008
Name
Description

Name

Data type

text

Alias
UMLS CUI [1]
C0027365
Unterschrift
Description

signature

Data type

text

Alias
UMLS CUI [1]
C1519316

Similar models

Dose-Limiting Toxicity (only cycle 1 and 2)

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
LeMLAR-Dosisstufe
C0178602 (UMLS CUI-1)
dose-limiting Toxicity
Item
Dose-limiting Toxicity DLT
boolean
C1512043 (UMLS CUI [1,1])
C0013221 (UMLS CUI [1,2])
date dose-limiting Toxicity
Item
Datum der DLT:
date
C0011008 (UMLS CUI [1,1])
C1512043 (UMLS CUI [1,2])
C0013221 (UMLS CUI [1,3])
patient ID
Item
Patientenidentifikation
integer
C1269815 (UMLS CUI [1])
dosage Methotrexate
Item
Methotrexat:
float
C3174092 (UMLS CUI [1,1])
C0025677 (UMLS CUI [1,2])
dose Cytarabine
Item
Cytarabin:
float
C3174092 (UMLS CUI [1,1])
C0010711 (UMLS CUI [1,2])
dose-limiting Toxicity
Item
Dosis-limitierende Toxizität in Zyklus 1
boolean
C1512043 (UMLS CUI [1,1])
C0013221 (UMLS CUI [1,2])
dose-limiting Toxicity
Item
Dosis-limitierende Toxizität in Zyklus 2
boolean
C1512043 (UMLS CUI [1,1])
C0013221 (UMLS CUI [1,2])
therapy continued
Item
Unzureichende Voraussetzung für die Therapiefortsetzung an Tag 8 (+ ≤ 3 Tage)
boolean
C3494713 (UMLS CUI [1])
therapy continued
Item
Unzureichende Voraussetzung für die Therapiefortsetzung an Tag 15 (+ ≤ 6 Tage)
boolean
C3494713 (UMLS CUI [1])
therapy continued
Item
Unzureichende Voraussetzung für die Therapiefortsetzung an Tag 29 (+ ≤ 7 Tage)
boolean
C3494713 (UMLS CUI [1])
therapy continued granulocyte
Item
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Granulozyten < 0.5/nl
boolean
C3494713 (UMLS CUI [1,1])
C0018183 (UMLS CUI [1,2])
therapy continued Blood Platelets
Item
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Thrombozyten < 25/nl
boolean
C3494713 (UMLS CUI [1,1])
C0005821 (UMLS CUI [1,2])
therapy continued Creatinine clearance measurement
Item
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Kreatinin-Clearance < 60 ml/min
boolean
C3494713 (UMLS CUI [1,1])
C0373595 (UMLS CUI [1,2])
therapy continued Bilirubin
Item
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Bilirubin ≥ 3.0 mg/dl
boolean
C3494713 (UMLS CUI [1,1])
C0005437 (UMLS CUI [1,2])
therapy continued GOT
Item
Unzureichende Voraussetzung für die Therapiefortsetzung wegen GOT ≥ 6 x obere Normgrenze
boolean
C3494713 (UMLS CUI [1,1])
C0201899 (UMLS CUI [1,2])
therapy continued GPT
Item
Unzureichende Voraussetzung für die Therapiefortsetzung wegen GPT ≥ 6 x obere Normgrenze
boolean
C3494713 (UMLS CUI [1,1])
C0201836 (UMLS CUI [1,2])
therapy continued mucositis
Item
Unzureichende Voraussetzung für die Therapiefortsetzung wegen Mukositis Grad 3 oder 4
boolean
C3494713 (UMLS CUI [1,1])
C0333355 (UMLS CUI [1,2])
Dosage Reduction Methotrexate
Item
Dosisreduktion von Methotrexat erforderlich
boolean
C0178602 (UMLS CUI [1,1])
C0441610 (UMLS CUI [1,2])
C0025677 (UMLS CUI [1,3])
dosage Methotrexate
Item
Verabreichte Dosis
float
C3174092 (UMLS CUI [1,1])
C0025677 (UMLS CUI [1,2])
day dosage Methotrexate
Item
An Tag
integer
C0439228 (UMLS CUI [1,1])
C3174092 (UMLS CUI [1,2])
C0025677 (UMLS CUI [1,3])
Dosage Reduction Cytarabine
Item
Dosisreduktion von Cytarabin erforderlich
boolean
C0178602 (UMLS CUI [1,1])
C0441610 (UMLS CUI [1,2])
C0010711 (UMLS CUI [1,3])
dosage Cytarabine
Item
Verabreichte Dosis
float
C3174092 (UMLS CUI [1,1])
C0010711 (UMLS CUI [1,2])
day dosage Cytarabine
Item
An Tag
integer
C0439228 (UMLS CUI [1,1])
C3174092 (UMLS CUI [1,2])
C0010711 (UMLS CUI [1,3])
Therapy Lenalidomide
Item
Lenalidomid-Therapie < 21 Tage pro Zyklus
boolean
C0087111 (UMLS CUI [1,1])
C1144149 (UMLS CUI [1,2])
toxicity Therapy cessation
Item
Anderweitige Toxizität, die die protokollgerechte Therapiefortführung verbietet
boolean
C0013221 (UMLS CUI [1,1])
C1699848 (UMLS CUI [1,2])
toxicity
Item
Beschreibung der Toxizität:
text
C0013221 (UMLS CUI [1])
UE-Number
Item
UE-Nummer(n):
integer
comments
Item
Weitere Kommentare
text
C0947611 (UMLS CUI [1])
date
Item
Datum der Bearbeitung
date
C0011008 (UMLS CUI [1])
Name
Item
Name
text
C0027365 (UMLS CUI [1])
signature
Item
Unterschrift
text
C1519316 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial